Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Quantitative gene-expression of the tumor angiogenesis markers vascular endothelial growth factor, integrin alphaV and integrin beta3 in human neuroendocrine tumors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genomic profiling of a combined large cell neuroendocrine carcinoma of the submandibular gland

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genetic analysis of an orbital metastasis from a primary hepatic neuroendocrine carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. CRTC1-MAML2 gene fusion in mucoepidermoid carcinoma of the lacrimal gland

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Genetic profiles distinguish different types of hereditary ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Anti-angiogenesis treatment is a promising new therapy for cancer that recently has also been suggested for patients with neuroendocrine tumors. The aim of the present study was therefore to investigate the level of tumor angiogenesis, and thereby the molecular basis for anti-angiogenesis treatment, in neuroendocrine tumors. We used quantitative real-time PCR for measuring mRNA gene-expression of vascular endothelial growth factor (VEGF), integrin alphaV, and integrin beta3, and CD34 for a group of patients with neuroendocrine tumors (n=13). Tissue from patients with colorectal cancer liver metastases (n=14) and normal liver tissues (n=16) was used as control. We found a lower mRNA level of VEGF in neuroendocrine tumors compared to both colorectal liver metastases (p<0.001) and normal liver tissue (p<0.01). For integrin beta3 there was also a borderline significant lower level of mRNA in neuroendocrine tumors compared to both colorectal liver metastases (p=0.10) and normal liver tissue (p=0.06). In neuroendocrine tumors, gene-expression was highly variable of VEGF (530-fold), integrin alphaV (23-fold) and integrin beta3 (106-fold). Quantitative gene-expression levels of the key angiogenesis molecules VEGF and integrin beta3 were lower in neuroendocrine tumors than in colorectal liver metastases and were highly variable. Therefore, individual selection of patients may be necessary if anti-angiogenesis treatment is to be successful in patients with neuroendocrine tumors.

OriginalsprogEngelsk
TidsskriftOncology Reports
Vol/bind21
Udgave nummer3
Sider (fra-til)769-75
Antal sider7
ISSN1021-335X
StatusUdgivet - mar. 2009

ID: 44962714